Advertisement

Long-term Functional and Oncologic Outcomes of Partial Adrenalectomy for Pheochromocytoma

Published:February 25, 2020DOI:https://doi.org/10.1016/j.urology.2020.02.015

      Abstract

      Objective

      To evaluate the recurrence and functional outcomes in a primarily hereditary cohort of patients undergoing partial adrenalectomy for pheochromocytoma.

      Methods

      A retrospective review from a prospectively managed database of patients undergoing partial adrenalectomy from 1995 to 2018 at the National Cancer Institute was performed. Local recurrence was defined as imaging evidence of a recurrent or de novo lesion on the operative side. Steroid dependency was defined as requiring daily steroid replacement at time of last follow-up.

      Results

      One hundred and twenty-four partial adrenalectomies, removing 162 tumors, were performed in 107 patients. Most patients had a known hereditary predisposition to develop bilateral, multifocal, and recurrent pheochromocytoma. Median tumor size was 2 cm (interquartile range (IQR) 1.5-2.8). Median follow-up was 60 months (IQR 13-131). Local recurrence occurred in 17 patients (15.8%) and were managed with active surveillance or surgery. A single patient (1/106, 0.9%) developed metastatic spread of pheochromocytoma approximately 14 years after his first of 2 partial adrenalectomies and remains alive under active surveillance. Median time to recurrence was 71 months (IQR 26-127) with 10 patients (9.3%) requiring daily steroid replacement at time of last follow-up.

      Conclusion

      Partial adrenalectomy offers excellent oncologic and functional outcomes, sparing most patients from lifelong steroid replacement therapy. Recurrences can be easily managed with repeat surgery or active surveillance via functional work-up and imaging. Partial adrenalectomy remains the recommended surgical management for patients pre-disposed to development of bilateral, multifocal and recurrent pheochromocytoma.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Urology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Tischler AS
        Pheochromocytoma and extra-adrenal paraganglioma: updates.
        Arch Pathol Lab Med. 2008; 132: 1272-1284
        • Fishbein L
        • Leshchiner I
        • Walter V
        • et al.
        Comprehensive molecular characterization of pheochromocytoma and paraganglioma.
        Cancer Cell. 2017; 31: 181-193
        • Neumann HPH
        • Bausch B
        • McWhinney SR
        • et al.
        Germ-line mutations in nonsyndromic pheochromocytoma.
        N Engl J Med. 2002; 346: 1459-1466
        • Jenny W
        • Peter S
        • Oliver G
        Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas.
        Endocr Relat Cancer. 2011; 18: R253-R276
        • Walther MM
        • Reiter R
        • Keiser HR
        • et al.
        Clincial and genetic characterization of pheocrhomocytoma in Von Hippel-Lindau Familys: comparison with sporadic pheochromocytoma gives insited into natorual history of pheochromocytoma.
        J Urol. 1999; 162: 659-664
        • Charmandari E
        • Nicolaides NC
        • Chrousos GP
        Adrenal insufficiency.
        Lancet. 2014; 383: 2152-2167
        • Walther MM
        • Keiser HR
        • Choyke PL
        • Rayford W
        • Lyne JC
        • Linehan WM
        Management of hereditary pheochromocytoma in Von Hippel-Lindau Kindreds with partial adrenalectomy.
        J Urol. 1999; 161: 395-398
        • Madala A
        • Daugherty M
        • Bratslavsky G
        Partial adrenalectomy—why should it be considered?.
        Urol Pract. 2015; 2: 359-366
        • Grubbs EG
        • Rich TA
        • Ng C
        • et al.
        Long-term outcomes of surgical treatment for hereditary pheochromocytoma.
        J Am Coll Surg. 2013; 216: 280-289
        • Nagaraja V
        • Eslick GD
        • Edirimanne S
        Recurrence and functional outcomes of partial adrenalectomy: a systematic review and meta-analysis.
        Int J Surg (London, England). 2015; 16: 7-13
        • Benhammou JN
        • Boris RS
        • Pacak K
        • Pinto PA
        • Linehan WM
        • Bratslavsky G
        Functional and oncologic outcomes of partial adrenalectomy for pheochromocytoma in patients with von Hippel-Lindau syndrome after at least 5 years of followup.
        J Urol. 2010; 184: 1855-1859
        • Asher KP
        • Gupta GN
        • Boris RS
        • Pinto PA
        • Linehan WM
        • Bratslavsky G
        Robot-assisted laparoscopic partial adrenalectomy for pheochromocytoma: the National Cancer Institute technique.
        Eur Urol. 2011; 60 ([Epub ahead of print]): 118-124
        • Perry RR
        • Keiser HR
        • Norton JA
        • et al.
        Surgical management of pheochromocytoma with the use of metyrosine.
        Ann Surg. 1990; 212: 621-628
        • Amar L
        • Servais A
        • Gimenez-Roqueplo AP
        • Zinzindohoue F
        • Chatellier G
        • Plouin PF
        Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma.
        J Clin Endocrinol Metab. 2005; 90: 2110-2116
        • Pamporaki C
        • Eisenhofer G
        • Fliedner S
        • et al.
        Characteristics of pediatric vs adult pheochromocytomas and paragangliomas.
        J Clin Endocrinol Metab. 2017; 102: 1122-1132
        • Hamidi O
        • Young JWF
        • Iñiguez-Ariza NM
        • et al.
        Malignant pheochromocytoma and paraganglioma: 272 patients over 55 Years.
        J Clin Endocrinol Metab. 2017; 102: 3296-3305
        • Hamidi O
        • Young WF
        • Gruber L
        • et al.
        Outcomes of patients with metastatic phaeochromocytoma and paraganglioma: a systematic review and meta-analysis.
        Clin Endocrinol. 2017; 87: 440-450
        • Jimenez C
        Treatment for patients with malignant pheochromocytomas and paragangliomas: a perspective from the Hallmarks of cancer.
        Front Endocrinol. 2018; 9 (277-277)
        • Roukounakis N
        • Dimas S
        • Kafetzis I
        • et al.
        Is preservation of the adrenal vein mandatory in laparoscopic adrenal-sparing surgery?.
        JSLS. 2007; 11: 215-218
        • Ikeda Y
        • Takami H
        • Niimi M
        • Kan S
        • Sasaki Y
        • Takayama J
        Laparoscopic partial or cortical-sparing adrenalectomy by dividing the adrenal central vein.
        Surg Endosc. 2001; 15: 747-750
        • Brauckhoff M
        • Gimm O
        • Thanh PN
        • et al.
        Critical size of residual adrenal tissue and recovery from impaired early postoperative adrenocortical function after subtotal bilateral adrenalectomy.
        Surgery. 2003; 134: 1020-1027
        • Tuncel A
        • Balci M
        • Aykanat C
        • Aslan Y
        • Berker D
        • Guzel O
        Laparoscopic partial adrenalectomy using near-infrared imaging: the initial experience.
        Minim Invasive Ther Allied Technol. 2019; : 1-7
        • Neumann HPH
        • Tsoy U
        • Bancos I
        • et al.
        Comparison of pheochromocytoma-specific morbidity and mortality among adults with bilateral pheochromocytomas undergoing total adrenalectomy vs cortical-sparing adrenalectomy.
        JAMA Netw Open. 2019; 2 (e198898-e198898)
        • Neumann HP
        • Bender BU
        • Reincke M
        • Eggstein S
        • Laubenberger J
        • Kirste G
        Adrenal-sparing surgery for phaeochromocytoma.
        Br J Surg. 1999; 86: 94-97
        • Walz MK
        • Alesina PF
        • Wenger FA
        • et al.
        Laparoscopic and retroperitoneoscopic treatment of pheochromocytomas and retroperitoneal paragangliomas: results of 161 tumors in 126 patients.
        World J Surg. 2006; 30: 899-908
        • Walz MK
        • Iova LD
        • Deimel J
        • et al.
        Minimally invasive surgery (MIS) in children and adolescents with pheochromocytomas and retroperitoneal paragangliomas: experiences in 42 patients.
        World J Surg. 2018; 42: 1024-1030
        • Gagner M
        • Lacroix A
        • Bolte E
        Laparoscopic adrenalectomy in Cushing's syndrome and pheochromocytoma.
        N Engl J Med. 1992; 327: 1033
        • Boris RS
        • Gupta G
        • Linehan WM
        • Pinto PA
        • Bratslavsky G
        Robot-assisted laparoscopic partial adrenalectomy: initial experience.
        Urology. 2011; 77: 775-780
        • Ball MW
        • Hemal AK
        • Allaf ME
        International consultation on urological diseases and European Association of Urology International Consultation on Minimally Invasive Surgery in Urology: laparoscopic and robotic adrenalectomy.
        BJU Int. 2017; 119: 13-21
        • Hyams ES
        • Stifelman MD
        The role of robotics for adrenal pathology.
        Curr Opin Urol. 2009; 19: 89-96